CircRNA-Regulated FXR/TLR4 Signaling and Ferroptosis in NiONP-Induced Hepatic Fibrosis

Study Background and Research Question

Nickel oxide nanoparticles (NiONPs) are increasingly prevalent in industrial applications. However, their propensity to accumulate in the liver and induce fibrosis is a growing toxicological concern. Liver fibrosis is characterized by excessive collagen deposition, primarily mediated by activated hepatic stellate cells (HSCs). While prior research links non-coding RNAs, nuclear receptor signaling, and ferroptosis—a form of iron-dependent cell death—to liver fibrogenesis, the interplay between these processes in the context of nanoparticle-induced injury remained unclear. Zhou et al. sought to unravel whether the circular RNA hsa_circ_0001944 could modulate the farnesoid X receptor (FXR)/Toll-like receptor 4 (TLR4) pathway and ferroptosis, thereby influencing collagen formation triggered by NiONPs in LX-2 (human HSC) cells (paper).

Key Innovation from the Reference Study

The pivotal advance of this research is the demonstration that hsa_circ_0001944 acts as an upstream regulator of the FXR/TLR4 axis and ferroptosis in HSCs. Specifically, the study reveals a mechanistic link between circRNA expression, nuclear receptor signaling, and iron-dependent cell death, culminating in altered collagen deposition in response to NiONP exposure. The use of molecular interventions—including FXR agonists, TLR4 inhibitors, and ferroptosis inducers—provided causal evidence for these pathways' roles. This positions hsa_circ_0001944 as a modulator of fibrosis through coordinated regulation of metabolic and inflammatory signals.

Methods and Experimental Design Insights

The investigators employed both in vivo rat models of liver fibrosis and in vitro LX-2 cell culture systems to recapitulate NiONP-induced fibrogenesis. Key methodological steps included:

• Assessment of FXR and TLR4 expression and ferroptosis markers in both models after NiONP treatment.
• Pharmacological modulation using GW4064 (a non-steroidal FXR agonist), TAK-242 (a TLR4 inhibitor), and Erastin (a ferroptosis agonist), either alone or in combination with NiONPs.
• Bioinformatics prediction and experimental manipulation (overexpression) of hsa_circ_0001944 to probe its regulatory role on FXR/TLR4 and ferroptosis pathways.
• Quantification of collagen deposition via measurement of COL1A1 and COL3A1 protein levels, as well as assessment of ferroptosis features, including lipid peroxidation markers and antioxidant enzyme activities.

Assay conditions were carefully optimized for each intervention to ensure relevance to human hepatic stellate cell physiology (paper).

Protocol Parameters

• assay: FXR activation in LX-2 cells | value_with_unit: 1 μM GW4064 | applicability: induction of FXR-dependent gene expression | rationale: Standard concentration for robust FXR activation in hepatic models | source_type: paper
• assay: NiONP-induced collagen deposition | value_with_unit: 20 μg/mL NiONPs | applicability: recapitulation of fibrogenic insult | rationale: Established dose for HSC activation and fibrosis marker induction | source_type: paper
• assay: TLR4 inhibition | value_with_unit: 1 μM TAK-242 | applicability: suppression of TLR4 signaling | rationale: Effective for selective TLR4 blockade in cell-based assays | source_type: paper
• assay: Ferroptosis induction | value_with_unit: 10 μM Erastin | applicability: promotion of ferroptotic features in HSCs | rationale: Dose validated for inducing lipid peroxidation and cell death | source_type: paper
• assay: hsa_circ_0001944 overexpression | value_with_unit: Plasmid transfection (amount not specified) | applicability: mechanistic interrogation of circRNA function | rationale: Standard molecular overexpression protocol | source_type: workflow_recommendation

Core Findings and Why They Matter

The authors report several interconnected findings:

• NiONP exposure leads to decreased FXR expression, increased TLR4 expression, and altered ferroptosis markers in both rat liver and LX-2 cells, coinciding with heightened collagen deposition (paper).
• Pharmacological activation of FXR with GW4064 suppresses TLR4 expression, augments ferroptosis features (increased lipid peroxidation and reduced glutathione activity), and attenuates collagen accumulation.
• TAK-242, a TLR4 inhibitor, also alleviates collagen deposition, primarily by enhancing markers of ferroptosis.
• Overexpression of hsa_circ_0001944 restores FXR levels, reduces TLR4, promotes ferroptosis, and mitigates fibrosis, even in the presence of NiONPs.

These results delineate a regulatory circuit where circRNA modulates nuclear receptor signaling and cell death pathways to counteract fibrogenic stimuli. The implication is twofold: (1) FXR acts as a negative regulator of TLR4-driven inflammation and collagen synthesis, and (2) ferroptosis serves as a protective mechanism against fibrogenesis. This provides a mechanistic rationale for targeting FXR and related signaling for antifibrotic intervention in nanoparticle-induced liver injury.

Comparison with Existing Internal Articles

Several recent internal resources also address GW4064's role as a non-steroidal FXR agonist in metabolic and fibrotic research:

• GW4064: Advanced FXR Agonist for Deciphering FXR/TLR4 Dynamics: This article provides an in-depth review of GW4064’s utility in dissecting the FXR/TLR4 pathway, closely paralleling the reference study’s mechanistic focus. Both works underline the importance of FXR activation in modulating inflammatory signaling and collagen turnover.
• GW4064: Unraveling FXR Signaling and Ferroptosis in Advanced Models: Expands the discussion to the role of GW4064 in regulating ferroptosis and bile acid metabolism, offering detailed molecular insights that complement the circRNA-mediated regulation highlighted by Zhou et al.
• Advancing Translational Metabolic Research: Strategic FXR Agonist Use: This source contextualizes GW4064’s translational value for metabolic and fibrotic disease models, reinforcing the practical implications of FXR activation in experimental workflows as demonstrated in the primary study.

Compared to these reviews, the reference paper uniquely integrates circRNA as a regulatory node upstream of FXR/TLR4/ferroptosis, advancing the mechanistic landscape and offering new avenues for targeted intervention.

Limitations and Transferability

While the study delivers strong mechanistic evidence in both rat and LX-2 cell models, certain limitations warrant consideration:

• Concentration ranges for pharmacological agents are validated for in vitro and rodent models; caution is needed before extrapolating to human in vivo scenarios (paper).
• The role of hsa_circ_0001944 was established predominantly via overexpression, and loss-of-function studies would further clarify its physiological importance.
• Ferroptosis was assessed using standard markers (e.g., lipid peroxidation, antioxidant enzymes), but direct cell death assays or in vivo ferroptosis modulation could strengthen the causal link.
• The study focuses on NiONP-induced fibrosis; transferability to other fibrogenic insults or broader metabolic disease contexts requires further empirical support.

Research Support Resources

For researchers seeking to model FXR activation in hepatic or metabolic research, GW4064 (SKU B1527) is a potent, selective non-steroidal FXR agonist (EC50: 15 nM in isolated assays; 90 nM in human FXR-transfected cells, source: product_spec). While GW4064 is not suitable for therapeutic use due to solubility and stability limitations, it remains a widely adopted tool compound for dissecting FXR-regulated signaling pathways—including those involving TLR4 and ferroptosis—in vitro and in animal models. Use of GW4064 should follow best practice for solution preparation and storage, as recommended by the supplier (workflow_recommendation).